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Lipid dropletsThe molecular motor dynein is regulated by the huntingtin protein, and Huntington's disease (HD) mutations
of huntingtin disrupt dynein motor activity. Besides abnormalities in the central nervous system, HD animal
models develop prominent peripheral pathology, with defective brown tissue thermogenesis and
dysfunctional white adipocytes, but whether this peripheral phenotype is recapitulated by dynein
dysfunction is unknown. Here, we observed prominently increased adiposity in mice harboring the legs at
odd angles (Loa/+) or the Cramping mutations (Cra/+) in the dynein heavy chain gene. In Cra/+ mice,
hyperadiposity occurred in the absence of energy imbalance and was the result of impaired norepinephrine-
stimulated lipolysis. A similar phenotype was observed in 3T3L1 adipocytes upon chemical inhibition of
dynein showing that loss of functional dynein leads to impairment of lipolysis. Ex vivo, dynein mutant adipose
tissue displayed increased reactive oxygen species production that was, at least partially, responsible for the
decreased cellular responses to norepinephrine and subsequent defect in stimulated lipolysis. Dynein
mutation also affected norepinephrine efﬁcacy to elicit a thermogenic response and led to morphological
abnormalities in brown adipose tissue and cold intolerance in dynein mutant mice. Interestingly, protein
levels of huntingtin were decreased in dynein mutant adipose tissue. Collectively, our results provide genetic
evidence that dynein plays a key role in lipid metabolism and thermogenesis through a modulation of
oxidative stress elicited by norepinephrine. This peripheral phenotype of dyneinmutant mice is similar to that
observed in various animal models of HD, lending further support for a functional link between huntingtin
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The cell cytoskeleton is a network of different types of ﬁlaments on
which molecular motors drive speciﬁc cargoes. Microtubules consti-
tute one of the major cytoskeletal ﬁlaments and two types of motors,
namely, cytoplasmic dynein (later referred as dynein) and kinesins,
use them as railroad tracks. Dynein is the only motor that drives
cargoes towards the minus end of microtubules and, as such, appears
responsible for most, if not all, the transport of cargoes from the cell
periphery towards the cell body. Dynein is involved in the late phases
of mitosis, and its function has been extensively studied in neurons inwhich it appears crucial for retrograde transport in axons [1] and
dendritic morphogenesis [2].
Studies on dynein functions have been previously hampered by the
lack of genetic tools. Indeed, the complexity of the motor, with
numerous subunits yielding a 2-million-Damolecular complex, renders
gain-of-function experiments currently impossible. Conversely,
embryos with ablated dynein heavy chain do not survive, showing the
important functions of dynein during development [3]. However, mice
withmildly compromised dynein function have been generated in 2003
by Hafezparast and collaborators [4]. These authors showed that two
independent mouse strains generated by N-ethyl-N-nitrosourea-
induced mutagenesis, Legs at odd angles (Loa) and Cramping 1 (Cra1,
further referred to asCra), harboreddominantly inheritedmissensepoint
mutations in the cargo-binding domain of the dynein heavy chain 1. The
Loa and Cramutations did not appear to affect basic cellular functions of
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dynein motors to sustain fast retrograde transport leading to a decreased
efﬁciency of these motors in situations of cellular stress [4,5] and
retrograde transport in adult Loa/+ motor neurons was decreased [4,5].
Homozygous mice die at birth, but heterozygous mice are viable and
present with a striking motor phenotype later ascribed to an early-onset
proprioceptive sensory neuropathy [6–8].
Dynein dysfunction is a potential causal mechanism in neurode-
generative diseases, most notably in degenerative diseases of the
striatum such as Huntington's disease (HD). Indeed, huntingtin, the
protein mutant in HD, and its associated protein HAP1 are binding
partners of dynein, and the activity of the dynein motor is positively
regulated by wild-type huntingtin and strongly decreased by HD-
associated mutations of huntingtin [9,10]. Our most recent studies
showed that Cra/+ mice developed striatal atrophy and its expected
behavioral and pathological consequences [11]. These results show
that a point mutation in dynein is sufﬁcient to lead to a pathology
analogous to HD, although milder.
Besides central nervous system pathology, it is increasingly
recognized that HD leads to a number of peripheral defects. Indeed,
HD-associated mutations of huntingtin have systemic effects on
energy metabolism. In particular, HD animal models develop defects
in both brown and white adipose tissues leading to compromised
lipolysis and thermogenesis [12–14]. Whether dynein dysfunction
leads to similar defects in the periphery remains unknown. We
studied here the peripheral phenotype of dynein mutant mice and
showed that dynein mutations compromise adipose tissue lipolysis
and thermogenesis. We further provide evidence that the defect
triggered by mutant dynein is due, at least in part, to increased
oxidative stress in response to norepinephrine. Interestingly, protein
levels of huntingtin were decreased in dynein mutant adipose tissue.
This peripheral phenotype of dynein mutant mice is similar to that
observed in various animal models of HD, lending further support for
a functional link between huntingtin and dynein.
2. Materials and methods
2.1. Animals
All the experiments were performed on male mice. Heterozygous
Cra/+ mice were F1 generation of a C57Bl6/C3H crossing and were
identiﬁed by tail DNA genotyping as described previously [4]. Wild-
type littermates were used as controls. Heterozygous Loa/+ mice
were in a pure C57Bl6 background. Mice were maintained at 23 °C
with a 12-h light/dark cycle and had food and water ad libitum. For
biochemical analysis, animals were sacriﬁced at the ages indicated in
the ﬁgures (2, 4, and 8 months of age), and tissues were quickly
dissected, frozen in liquid nitrogen, and stored at−80 °C until use. All
animal experiments were performed under the supervision of
authorized investigators and followed current EU regulations. For
the high-fat diet (HFD) experiments, C57Bl6/C3H wild-type mice
were fed with chow diet supplemented with 20% (wt/wt) saturated
fat.
2.2. RT-qPCR
Real-time RT quantitative PCR was performed as described [7]. The
relative levels of each RNA were normalized to the corresponding
polymerase II RNA levels. Table S1 indicates the primers used for qPCR.
2.3. Histology
For adipose tissues histology, 24-h post-ﬁxed tissues were
embedded in parafﬁn and cut on a microtome into slices of 16-μm
thickness. Sections were then deparafﬁnized and rehydrated before
hematoxylin and eosin staining and then dehydrated for observation.2.4. Leptin ELISA
Leptin levels in serumwere measured using an ELISA kit from Assay
Pro (St. Charles, MO, USA), following instructions of the manufacturer.
2.5. Indirect calorimetry
We measured O2 consumption and CO2 production by using an
open-circuit indirect calorimetry system (Klogor, Lannion, France) as
described [15]. Energy expenditure was calculated during a 24-h cold
challenge at 7 °C.
2.6. Body composition analysis
Carcasses were freeze-dried to constant mass and ground under
liquid nitrogen to a ﬁne homogenous powder kept at −20 °C until
chemical analysis. Samples were lyophilized for 48 h just before
analysis to eliminate any traces of water. Body lipid content was
determined on duplicate samples by a solvent extraction procedure
(chloroform/methanol; 2/1, v/v) adapted from Folch et al. [16] on 1 g
of powder. The nitrogen content of the carcass was determined in
triplicate using the Kjeldahl method on 100–150 mg of sample.
Protein content was calculated as nitrogen content *6.25. Ash content
wasmeasured on duplicate 1- to 2-g samples after total combustion at
400 °C for 24 h in a mufﬂe furnace.
2.7. Western blot
White adipose tissue (WAT) pads were lysed and homogenized in a
protein extraction buffer (PBS 1×, 0.1% SDS, 0.2% IGEPAL, 1% deoxycho-
late, 1×protease inhibitor cocktail, and1×phosphatase inhibitor) using a
Potter homogenizer (VWR, Strasbourg, France). Protein quantiﬁcation
was carried out using a BCA assay kit (Interchim, Montlucon, France).
Equal amounts of soluble proteins were denaturated by boiling, resolved
by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to a nitrocellulose membrane. After blocking in
10% non-fat dry milk in wash buffer for 30 min, and probing with a
speciﬁc primary antibody targeted at hormone-sensitive lipase (HSL),
HSL phosphorylated at Serine 563 (P-HSL(Ser-563)), adipose triglyceride
lipase (ATGL), and a phosphorylated formof a PKA substrate (PKA-S) (all
from Cell Signaling, Boston, MA) and actin (Sigma-Aldrich, Lyon, France)
and a horseradish peroxidase (HRP)-conjugated secondary antibody
(Jackson Immunoresearch, Suffolk, United Kingdom), the protein
bands were detected by chemiluminescence and X-ray ﬁlm exposure
(GE healthcare, Chalfont St. Giles, United Kingdom). Results were
quantiﬁed using imageJ software [17].
2.8. WAT explants and lipolysis assays
Epididymal WAT was dissected immediately after sacriﬁce, weighed,
andmincedwith scissors inwarmglucose-free Krebs–Ringer bicarbonate
buffer, pH 7.4 containing 4% BSA. Samples were incubated in 3 ml of
buffer, pretreated or not with 1 mM EHNA (erytro-9-(2-Hydroxy-3-
nonyl) adenine hydrochloride, Sigma-Aldrich, Lyon France) or 10 μM
apocynin for 15 min, and then stimulated with 10 μM isoproterenol or
10 μM forskolin. Incubation medium was collected and assayed for
glycerol content (Randox, Antrim, United Kingdom). Glycerol levels were
normalized to the corresponding tissue weight. Similar results were
obtained by standardization with protein content (not shown).
2.9. Cell culture and treatments
3 T3-L1 pre-adipocytes from ATCC (Manassas, USA) were grown
until conﬂuence in DMEM high glucose containing 10% FCS and 1%
penicillin/streptomycin in plates coated with 0.01% collagen. After
2 days of conﬂuence, cells were differentiated into adipocytes by
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streptomycin, 1 μM dexamethasone (Sigma-Aldrich, Lyon, France),
0.5 mM of IBMX (3-isobutyl-1-methylxanthine, PDE inhibitor)
(Sigma-Aldrich, Lyon France), and 1 μM insulin (Sigma-Aldrich,
Lyon France) during 2 days. Cells were further maintained for 6 days
in DMEM high glucose containing 10% FCS, 1 μM insulin, and 1%
penicillin/streptomycin before experiments.
For lipolysis experiments, 4 h starved differentiated 3T3-L1 were
pretreated with 1 mM EHNA for 15 min and stimulated with 10 μM
isoproterenol (Sigma-Aldrich, Lyon, France) in the presence of
0.5 mM IBMX for 4 h. Lipid droplets were stained with bodipy 493/
503 (Invitrogen, Cergy-Pontoise, France) and nuclei with Hoechst.
Lipid droplets were visualized using epiﬂuorescence microscopy. ForFig. 1. Increased adiposity in dynein mutant mice. All values are indicated as mean±SEM.W
or Loa/+) using open symbols. (A) Epididymal white adipose tissue (WAT) fat pad weight in
*pb0.05 vs. corresponding +/+ in Student's t-test. (B) Epididymal WAT fat pad weight i
corresponding +/+ in Student's t-test. (C) Representative photomicrograph showing WAT
mice and their corresponding +/+ mice stained with hematoxylin and eosin. Note the str
peroxisome proliferation activating receptor γ (PPARγ), adipocyte protein 2 (aP2), and lipopr
*pb0.05 vs. +/+ (n=5–8 mice per group). (E) Leptin levels in serum from+/+ and Cra/+
Western blotting of adipose triglyceride lipase (ATGL), hormone-sensitive lipase (HSL), andquantiﬁcation of the diameter of lipid droplets, we measured the area
of the ﬁve largest lipid droplets per cell by using ImageJ software. This
cutoff of 5 droplets per cell was chosen because (i) all cells studied
showed at least 5 droplets and (ii) it was not possible to measure the
diameter of most small droplets in conditions treated with isoproter-
enol (see Fig. 4B).
2.10. Oxidative stress measurements
WAT explants were incubated with 5 μM hydroethidine during
15 min and further stimulated with 10 μM isoproterenol. Tissues were
immediately ﬁxed in 4% PFA and mounted for observation. H2O2
production was measured with Amplex Red reagent (Invitrogen,ild-type mice (+/+) are indicated using black symbols and dynein mutant mice (Cra/+
grams of +/+ and Cra/+mice of 4 (4mo) and 8 (8mo) months of age. N=8 per group.
n g of +/+ and Loa/+ mice of 5 (5mo) months of age. N=7 per group. *pb0.05 vs.
sections of 8-month-old Cra/+ (upper panels) and 5-month-old Loa/+ (lower panels)
ong increase in adipocyte size. Scale bar=25 μm. (D) mRNA levels of leptin, perilipin,
otein lipase (LPL) in the epididymalWAT from+/+ and Cra/+mice at 4 months of age.
mice at 4 months of age. *pb0.05 vs. +/+ (n=4–8 mice per group). (F) Representative
actin in the epididimary WAT from 4-month-old +/+ and Cra/+ mice.
Fig. 2. Normal energy balance in dyneinmutantmice. (A) Bodyweight of wild-type (+/+, black columns) and dyneinmutant (Cra/+)mice at 2 (2mo), 4 (4mo), and 8 (8mo)months of age.
*pb0.05 vs.+/+(n=5–8miceper group). (B) Resting (REE) and total (TEE) energy expenditure ofwild-type (+/+, black columns) anddyneinmutant (Cra/+)mice at 4 months of age. There
is no global decrease in energy expenditure in dynein mutant mice at this age. No signiﬁcant difference is observed. N=6 per group. (C) Food intake of wild-type (+/+, black columns) and
dyneinmutant (Cra/+)mice at 4 (4mo) and 8 (8mo) months of age. No signiﬁcant difference is observed. N=10 per group (D) Overnight spontaneous locomotor activity as measured using
infrared beams in wild-type (+/+, black columns) and dynein mutant (Cra/+) mice at 4 (4mo) months of age. No difference is observed between both genotypes. N=12 per group.
Table 1
Body composition of dynein mutant mice.
+/+, 4 Months (n=9) Cra/+, 4 Months (n=9)
Body weight, g 28.7±1.0 30.3±1.2
Water, % 61.9±1.3 59.9±1.2
Proteins, g 5.66±0.14 5.92±0.15
Proteins, % 19.8±0.5 19.6±0.5
Lipids, g 4.24±0.65 5.55±0.83
Lipids, % 14.5±1.7 17.8±1.8
Minerals, g 1.13±0.03 1.12±0.03
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etry catalyzed by HRP (Fluka Biochemika, Lyon, France) to yield the
ﬂuorescent compound resoruﬁn and molar equivalent O2. ResoruﬁnFig. 3.Dynein isexpressed in theWATand regulatedbyhigh-fat feeding. (A)RT-PCRanalysis of dy
4 months of age. Note the broad expression pattern of dynein outside the CNS. (B) RT-PCR analys
The primers used for DHC cDNA ampliﬁcation span the Cramutation, and thismutation deletes a
panel, DHC+RsaI) allows distinguishing between RsaI-resistant Cra mutation bearing cDNAs a
(n=8). The results indicate that both DHC alleles (wild type and Cra) are expressed in theWAT.
adipose tissue from wild-type mice fed with chow (−) or high-fat diet (HFD, +). *pb0.05 vs. c
epididimary white adipose tissue from wild-type mice fed with chow (−) or high-fat diet (HFDhas excitation/emission characteristics of 563/587 nm and is
extremely stable once formed. Fluorescence was measured continu-
ously [change in ﬂuorescence (ΔF)/s] with a Fluoromax 4 (Jobin Yvon,
Longjumeau, France) spectroﬂuorometer with temperature control
and magnetic stirring. After baseline, ΔF (reactants only) was
established, the reaction was initiated by addition of a weighed
amount of minced WAT to 600 μl of buffer Z containing (in mM) 110
K-MES, 35 KCl, 1 EGTA, 10 K2HPO4, and 3 MgCl2 (pH 7.3 at 37 °C). We
ﬁrst added 5 μMAmplex Red and 0.5 U/ml HRP. We recorded baseline
production of H2O2 in these conditions and then added 10 μM
isoproterenol to stimulate lipolysis. After 3 min of recordings, we
added 10 μM apocynin and further recorded ﬂuorescence for 3 min.
H2O2 production rate was calculated from the slope of ΔF/s, after
subtracting background, from a standard curve established with theneinheavy chain (DHC) and18S ribosomalRNA invarious tissues of+/+andCra/+miceof
is of dynein heavy chain (DHC) and 18S ribosomal RNA in theWAT of+/+ and Cra/+mice.
n endogenous RsaI site. Thus, digestion of the ampliﬁed DHC PCR product with RsaI (middle
nd RsaI-sensitive wild-type cDNAs. Two representative mice of each genotype are shown
(C)mRNA levels of dynein heavy chain (DHC), leptin and perilipin in the epididimarywhite
how. n=6 mice per group. (D) Representative Western blotting of ATGL and actin in the
, +).
63J. Eschbach et al. / Biochimica et Biophysica Acta 1812 (2011) 59–69appropriate reaction conditions. H2O2 production was expressed as
picomoles per minute per milligram of wet weight.2.11. Statistical analysis
Statistical comparisons were accomplished with the unpaired
Student's t-test for comparison of two groups or ANOVA followed by
the post hoc Newman–Keuls multiple comparisons test for multiple
comparisons using PRISM version 2.0a software (GraphPad, San
Diego, USA).Fig. 4. Dynein involvement in adipose lipolysis. All values are indicated as mean±SEM. (
norepinephrine injection in +/+ and Cra/+ mice (Cra/+) of 4 months of age. N=6 mice pe
condition. (B) Glycerol release in nmol/mg of tissue of WAT explants from +/+ and Cra/+ m
condition. *pb0.05 vs. corresponding+/+.A representative experiment out of 4 independent e
typemice in basal or stimulatedby isoproterenol conditions in thepresenceor absence of EHNA
vs. corresponding unstimulated condition; #pb0.05 vs. corresponding condition without
(D) Representative photomicrographs showing differentiated 3T3L1 stimulated or unstimulat
presence or absence of EHNA. Neutral lipids are stained using Bodipy493/503 and nuclei are sta
the number of droplets but strongly decreases their surface. EHNA coapplication prevente
corresponding unstimulated condition; #pb0.05 vs. corresponding condition without EHNA. A3. Results
3.1. Hyperadiposity in the absence of energy imbalance in dynein mutant
mice
To explore the potential role of dynein in adipocytes, we usedmice
heterozygous for the Cramping mutation (Cra/+) and the Legs at odd
angles mutation (Loa/+). Both Loa/+ and Cra/+ mice showed
increased weight of the white adipose tissue (WAT), including
epididymal (Fig. 1A and B), interscapular and retroperitoneal (data
not shown) fat pads. Interestingly, increased mass of the fat pads wasA) NEFAs levels in mmol/l before (black columns) and 20 min after (open columns)
r group. *pb0.05 vs. corresponding “before” condition; #pb0.05 vs. corresponding +/+
ice of 2 months of age in basal (left panel) or stimulated by isoproterenol (right panel)
xperiments is shown. (C) Glycerol release in nmol/mgof tissue ofWATexplants fromwild-
.Measuresweredone after 15 (left) or 90 min (right) of isoproterenol stimulation. *pb0.05
EHNA. A representative experiment out of 3 independent experiments is shown.
ed with isoproterenol and the PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) in the
inedwithHoechst 33342. Note that the stimulationwith isoproterenol and IBMX increases
d this effect. (E) Quantiﬁcation of the experiments presented in panel E. *pb0.05 vs.
representative experiment out of 3 independent experiments is shown.
Fig. 5. Defective lipolysis in dyneinmutantWAT is associatedwith defective β-adrenergic
signaling. All values are indicated as mean±SEM. Wild-type mice (+/+) are indicated
using black symbols and dynein mutant mice (Cra/+) using open symbols.
(A) Representative Western blotting of phosphorylated Ser 563 hormone-sensitive lipase
(P-HSL), total hormone-sensitive lipase (HSL), phosphorylated PKA substrate immuno-
reactivity (PKA-S), and actin of +/+ and Cra/+ mice WAT explants treated for 3 h with
(Iso) orwithout (vh, vehicle) 10 μMof isoproterenol. (B)Quantiﬁcationof the experiments
presented in panel A. Four independent experiments were performed. *pb0.05 vs. +/+.
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progressed with age. Adipocytes of Cra/+ and Loa/+ mice were
larger than those of their corresponding+/+mice at 8 months of age
(Fig. 1C). Before that age, mRNAs of perilipin and leptin, two genes
whose expressions are correlated with adipose mass were increased
in epididymal fat of 4-month-old Cra/+mice (Fig. 1D) and circulating
levels of leptin were increased at 4 months of age (Fig. 1E). Increased
adipose mass was not due to enhanced adipogenesis since the
expression of adipogenic genes such as PPARγ, aP2, and LPL were
unchanged (Fig. 1D). Consistent with increased adiposity, adipose
triglyceride lipase (ATGL) protein levels increased at 4 months of age
in dynein mutant WAT, while hormone-sensitive lipase (HSL) protein
levels were unchanged (Fig. 1F). Hyperadiposity might be driven by
changes in energy balance of the animal, for instance, by increased
energy intake or decreased energy expenditure. Despite an already
detectable hyperadiposity, Cra/+ mice were not obese at 2 or
4 months of age, but only at 8 months of age (Fig. 2A). Resting and
total energy expenditure (Fig. 2B), food intake (Fig. 2C), and
spontaneous locomotor activity (Fig. 2D) were unchanged at
4 months of age. Furthermore, despite a trend towards increased
lipid content, body composition of Cra/+ mice was not signiﬁcantly
different from that of wild-type littermates at 4 months of age
(Table 1), suggesting that increased WAT deposition in these animals
was compensated by decreased lipid content in other tissues.
Altogether, dyneinmutantmice developed increasedWAT deposition,
in the absence of detectable energy imbalance.
3.2. Dynein is expressed in white adipose tissue
The increase in WAT accumulation suggested that dynein was
involved in adipose tissue lipid metabolism. Such an involvement
could be direct, through dynein action in adipocytes, or indirect,
through an impairment of CNS-derived cues. If dynein has a function
in lipid metabolism in WAT, it should ﬁrst be expressed in this tissue.
Indeed, mRNA levels of dynein heavy chain (DHC) were detectable in
WAT and many other non-CNS tissues (Fig. 3A). Moreover, mutant
DHC mRNA was observed in WAT of Cra/+ mice (Fig. 3B). Consistent
with a role in lipid metabolism, DHC mRNA levels mildly but
signiﬁcantly increased after 3 weeks of high-fat feeding in wild-type
mice, in a manner similar to perilipin mRNA (Fig. 3C). In these
experiments, the large increases in leptin mRNA (Fig. 3C) and ATGL
protein levels (Fig. 3D)were consistent with efﬁcient high-fat feeding.
Thus, dynein is expressed in adipocytes and regulated by high-fat
feeding, consistent with a function in lipid metabolism.
3.3. Dynein activity is required for norepinephrine-induced lipolysis
We next explored whether intrinsic defects in adipose tissue could
be the cause of WAT accumulation in dynein mutant mice. The CNS
mostly controls adipose tissue energy metabolism through activation
of the sympathetic nervous system. Thus, if adipose tissues of Cra/+
mice were normal and the increased adiposity of Cra/+ mice was the
result of a “pure” CNS defect, their responses to norepinephrine
should be similar to those of +/+ littermates. Obesity is a
confounding factor since development of obesity leads to blunted
norepinephrine-stimulated lipolysis [18]. To take this factor into
account, we performed lipolysis experiments in 4-month-old mice,
i.e., an age when adiposity was increased but mice were not obese and
not insulin-resistant (not shown). In WAT, sympathetic activation
stimulates lipolysis leading to enhanced release of NEFAs. When+/+
mice were challenged with norepinephrine, blood levels of NEFAs
almost doubled 20 min after injection. In contrast, Cra/+ mice
injected in parallel showed only a non-signiﬁcant 25% increase in
NEFAs levels (Fig. 4A). In order to directly measure lipolysis, we
cultured WAT explants of +/+ and Cra/+ mice at 4 months of age,
stimulated them with norepinephrine, and measured glycerol in theculture medium as lipolysis index. As shown in Fig. 4B, lipolysis was
unchanged in basal conditions, but after norepinephrine stimulation,
the lipolytic response was twofold less in Cra/+ than in +/+ mice.
Similar results were obtained by standardizing either by tissue weight
or protein content (not shown). We next sought to determine
whether pharmacological inhibition of dynein ATPase activity also
inhibited lipolysis. For this, we used explants of WAT from wild-type
animals and treated them or not with EHNA, a widely documented
inhibitor of dynein ATPase activity [19,20]. Consistent with the results
obtained in Cra/+ mice, basal lipolytic activity of WAT explants was
unchanged by EHNA treatment while norepinephrine-stimulated
lipolysis was completely blunted by EHNA coapplication (Fig. 4C).
To further document this point, we turned to the differentiated 3T3L1
cell line. In these cells, multiple lipid droplets are readily observable in
the cytosol. The diameter of lipid droplets increased with EHNA
treatment (Fig. 4D), suggesting that dynein inhibition resulted in
increased lipid storage in these cells. Furthermore, the decrease in
droplet diameter elicited by isoproterenol treatment was potently
inhibited by EHNA coapplication (Fig. 4D–E). Thus, here again, dynein
ATPase activity was required for adipocyte lipolysis.
3.4. Decreased lipolysis in dynein mutant WAT is associated with defective
β-adrenergic signaling and due to increased oxidative stress
To deﬁne the mechanisms underlying defective lipolysis in dynein
mutantmice, weﬁrst studiedβ-adrenergic signaling. The expressions of
HSL and β2 adrenergic receptor were roughly normal in Cra/+ WAT
(Fig. S1), and HSL protein levels were unchanged (Fig. 1E). Upon
isoproterenol stimulation,WAT explants of Cra/+mice showedblunted
phosphorylation of HSL (Fig. 5A–B). PKA activity, as evaluated by PKA
substrate immunoreactivity, appeared, however, not signiﬁcantly
decreased (Fig. 5A–B). Thus, dynein mutation triggered speciﬁcally
abnormal PKA-mediated phosphorylation of HSL. However, direct
adenylate cyclase activation by forskolin did not correct lipolysis
deﬁciency (Fig. S2), showing that the defect was independent of
adenylate cyclase activation. Beta-adrenergic stimulation is known to
modulate hydrogen peroxide production in adipocytes through PKA-
independent pathways [21,22]. Interestingly, hydrogen peroxide is
known to inhibit norepinephrine-induced lipolysis [23,24], and drugs
interfering with the stability of microtubules, i.e., the dynein railroad
tracks, are known to increase oxidative stress through NADPH oxidase
activation [25,26]. To directly study whether dynein mutation might
lead to exacerbated oxidative stress, we measured H2O2 production in
response to norepinephrine stimulation. Consistent with previous
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stimulation (Fig. 6A). H2O2 was less in basal conditions in Cra/+ WAT
explants, but potently stimulated after isoproterenol stimulation
(Fig. 6A). InWAT, oxidative stress is largely NADPH oxidase-dependent
[27] and inhibition of NADPH oxidase with apocynin completely
abolished H2O2 production in both Cra/+ and +/+ mice (Fig. 6A). To
further document the existence of oxidative stress in Cra/+ WAT after
norepinephrine stimulation, we treated WAT explants with the
superoxide probe hydroethidine, which yields a nuclear ﬂuorescent
stainingwhen superoxide is produced.Uponnorepinephrine treatment,
nuclei ofCra/+WATbecamebrightlyﬂuorescent, aneventnot observed
in+/+WATexplants (Fig. 6C).Wenextmeasured the expression levels
of NADPH oxidase subunits (gp47 and gp91) in WAT, as well as knownFig. 6. Defective lipolysis in dynein mutantWAT is due to oxidative stress leading to defective
are indicated using black symbols and dynein mutant mice (Cra/+) using open symbol
isoproterenol (Iso), and isoproterenol+10 μM apocynin (Iso+Apo) treatments. *pb0.05 vs
monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), Cu/Zn superoxide dismutase
(gp91) in white adipose tissue from +/+ and Cra/+ mice at 4 months of age. *pb0.05 vs
explants 15-min exposure to 10 μM isoproterenol or vehicle. Note that a number of nuclei are
superoxide production. (D) Glycerol release in nmol/mg of tissue of white adipose tissue exp
mice in the presence (open circles) or absence (black circles) of 10 μM apocynin. *pb0.05 vs
experiments is shown. (E) RepresentativeWestern blotting of phosphorylated Ser 563 horm
+ mice WAT explants treated for 3 h with 10 μM isoproterenol in the absence (Iso) or presantioxidant enzymes (SOD1 and glutathione peroxidase), and NFkap-
paB targets induced after oxidative stress (MCP-1 and IL6). All these
genes were intensely up regulated in Cra/+ mice WAT at 4 months of
age (Fig. 6B). Although theseupregulationsdonot necessarilymean that
the corresponding proteins are increased, their coordinations provide
indirect evidence of a potent antioxidant response. Last, in order to
determine whether the defect in lipolysis was due to NADPH-oxidase-
dependent oxidative stress, we treated WAT explants with apocynin
and followed glycerol release upon isoproterenol stimulation. In these
experiments, apocynin partially reverted Cra/+ defect in stimulated
lipolysis (Fig. 6D) and restored HSL phosphorylation (Fig. 6E). Thus,
dynein mutation limits stimulated lipolysis through a deregulation of
endogenous oxidative stress.β-adrenergic signaling. All values are indicated as mean±SEM.Wild-type mice (+/+)
s. (A) H2O2 production in +/+ and Cra/+ WAT explants after vehicle (Vh), 10 μM
. corresponding wild type, $pb0.05 vs. corresponding Iso condition. (B) mRNA levels of
(SOD1), glutathione peroxidase (Gpx), NAPDH oxidase subunits gp47 (gp47) and gp91
. +/+ (n=5–7 mice per group). (C) Hydroethidine staining in +/+ and Cra/+ WAT
brightly stained in treated Cra/+WAT showing that isoproterenol treatment increased
lants stimulated by 10 μM isoproterenol from+/+ (left panel) and Cra/+ (right panel)
. corresponding untreated condition. A representative experiment out of 3 independent
one-sensitive lipase (P-HSL), and total hormone-sensitive lipase (HSL), of +/+ and Cra/
ence (Iso+Apo) of 10 μM apocynin.
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We next sought to determine whether the defect in lipolysis was
restricted to the WAT. The interscapular brown adipose tissue (BAT)
waspaler (not shown) and increased in size at 4 monthsof age (Fig. 7A),
and brown adipocytes accumulated fat as observed on histological
sections of both Cra/+ and Loa/+ BAT (Fig. 7B). This abnormal BAT
phenotypewas not due to transcriptional downregulation of UCP1 since
mRNA levels of both UCP1 and PGC1α, one of its key activators, were
unchanged at 4 months of age. Cra/+ mice displayed normal rectal
temperature at 4 months of age but were hypothermic at 8 months of
age (Fig. 8A). BAT functionwas, however, already abnormal at 4 months
of age since a 4-h cold challenge leads to hypothermia in Cra/+mice in
4- and 8-month-old mice (Fig. 8B and data not shown). Furthermore,
4-month-old Cra/+ mice were unable to increase energy expenditure
upon cold at levels similar to +/+mice (Fig. 8C).We reasoned that the
BAT defect resulted also from a decreased response to norepinephrine.
To test this hypothesis, we challenged Cra/+micewith norepinephrine
andmeasured their oxygen consumption (Fig. 8D). The burst in oxygen
consumption after norepinephrine injection reﬂects sympathetic-like
BAT activation. We observed that saline injection led to a transient
increase in oxygen consumption during the ﬁrst 15 min after the
injection, an increase probably due to the stress response induced byFig. 7. Defective brown adipose tissue morphology in dynein mutant mice.
(A) Interscapular brown adipose tissue (BAT) weight of wild-type (+/+, black
columns) and dynein mutant (Cra/+, empty columns) mice at 4 months (4mo) of age.
*pb0.05 vs. +/+ (n=6–8 mice per group). (B) Representative photomicrograph
showing BAT sections of 8-month-old Cra/+ (upper panels) and 5-month-old Loa/+
(lower panels) mice and their corresponding +/+ mice stained with hematoxylin and
eosin. Note the prominent appearance of fat vesicles. Scale bar=25 μm. (C) mRNA
levels of mitochondrial uncoupling protein 1 (UCP1) and PPARγ-coactivator 1 α
(PGC1α) in the BAT from wild type (+/+, black columns) and dynein mutant (Cra/+,
empty columns) at 4 months of age. *pb0.05 vs. +/+ (n=5–7 mice per group).animal handling. However, the increase in oxygen consumption was
sustained at least 30 min after norepinephrine injection (Fig. 8D). Most
interestingly, norepinephrine-evoked oxygen consumptionwas strong-
ly decreased in Cra/+mice as comparedwith+/+ littermates (Fig. 8E).
In all, our results obtained in vivo, ex vivo, and in vitro all converge to
ascertain a key role to dynein in the control of adipose tissue lipolysis
underlying lipid accumulation in the WAT and dysfunctional BAT-
mediated thermogenesis. These defects are intrinsic to adipose tissues
and independent of other CNS-linked consequences of dyneinmutation.
3.6. Dynein mutation decreases levels of huntingtin in the WAT
The previous results obtained in WAT and BAT of dynein mutant
animals are reminiscent of HD-associated defects observed in animal
models of HD [13,14,28,29]. To strengthen the analogy between the
animal models, we studied the expression levels of huntingtin and its
associated protein HAP-1 [30,31] in WAT of dynein mutant mice.
Huntingtin, but not HAP-1, was expressed at signiﬁcant levels in WAT
(results not shown) and huntingtinmRNA levels appeared unchanged
in WAT of 4-month-old dynein mutant mice (Fig. 9A). Interestingly,
however, protein levels of full-length huntingtin were decreased in
the WAT of 4-month-old dynein mutant mice (Fig. 9B). Thus, the
dynein mutation led to decreased huntingtin protein levels in adult
WAT.
4. Discussion
The molecular motor dynein is ubiquitously expressed in adult
animals, including in post-mitotic cells, yet its role remains obscure in
adult cells other than neurons. Our results document a previously
unknown function for dynein in adipose tissue response to norepineph-
rine and lipolysis. The dynein-mutant-associated defect in lipolysis was
due to a dysfunctional β-adrenergic signaling and appeared to be, at least
in part, dependent on NADPH-oxidase-derived oxidative stress. These
ﬁndings deﬁne dynein as a novel potential actor in energy homeostasis
that could be of interest for type 2 diabetes. Furthermore, the peripheral
phenotype described here in dynein mutant mice is strikingly similar to
that of various animal models of Huntington's disease, further supporting
the idea that dynein and huntingtin are functionally linked.
4.1. The adipocyte phenotype of dynein mutant mice is independent of
the central nervous system
Dynein function has been largely studied in the CNS, yet this motor is
ubiquitously expressed. We show here that dynein function is critical in
the responseof adipose tissues tonorepinephrine. This requirement is due
to a function of dynein in adipocytes themselves and is not a secondary
consequence of a CNS abnormality in dyneinmutantmice. Several lines of
evidence support this claim. First, dynein is expressed in adipose tissue
and regulated in amanner consistentwith a function in lipidmetabolism.
Second, the WAT phenotype occurs in early adulthood, long before
neurodegeneration was thought to occur [4]. Third, the defect in lipolysis
is recapitulated ex vivo, in the absence of CNS-derived cues and in vitro
upon chemical inhibition of dynein. Fourth, this defect occurred in mice
with normal energy balance,most notablywith normal energy intake and
energy expenditure. This, however, does not fully exclude a CNS inﬂuence
on the adipose phenotype. The generation of conditional knock out
animals will be a necessary step to solve this question.
4.2. Dynein is required at several steps in lipid metabolism
The dyneinmotor has been ﬁrmly established as amajor actor in lipid
droplet formation [32–36]. First, anRNAi-based functional screenrevealed
that dynein knockdown resulted in strikingly diminished lipid accumu-
lation in Drosophila cells [36]. Furthermore, dynein is a component of
mammalian lipid droplets [32] and appears required for the formation of
Fig. 8. Defective brown adipose tissue thermogenic function in dynein mutant mice. (A) Rectal temperatures in basal conditions in 4 (4mo)- and 8 (8mo)-month-old wild-type (+/+,
black columns) and dyneinmutant (Cra/+, empty columns)mice.N=8per group. *pb0.05 vs. corresponding+/+. (B) Rectal temperatures after a 4-h cold challenge (7 °C) in 4-month-
old wild-type (+/+, black columns) and dynein mutant (Cra/+, empty columns) mice. N=8 per group. *pb0.05 vs. corresponding +/+. (C) Total energy expenditure of 4-month-old
wild-type (+/+, black columns) and dynein mutant (Cra/+, empty columns) mice during a 24-h cold challenge (7 °C). N=8 per group. *pb0.05 vs. +/+. (D–E) Norepinephrine
challenge: energy expenditure expressed in percentage of the baseline for +/+ (black squares), Cra/+ (open squares), and mice injected with saline (vehicle, black circles).
Norepinephrine was injected intraperitoneally at t0 (arrow), and energy expenditure was measured during 1 h after the injection. The ﬁrst 15 min (dark grey) was discarded for the
quantiﬁcation due to the strong effect of the injection per se (see the strong increase in energy expenditure invehicle-injectedmice).Measures from15 to 30 min (light grey)wereused for
the quantiﬁcation in panel E. ***pb0.001 vs. condition shown.
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differentiated 3T3L1 cells increased the size of lipid droplets not only in
isoproterenol treated cells but also in basal conditions, consistent with
dynein involvement in lipid droplet trafﬁcking [32,34]. This function of
dynein resembles that demonstrated for perilipin [37] or caveolin 1 [38],
both of these proteins being involved in lipid droplet formation in
adipocytes. Nevertheless, and contrary to either perilipin −/− or
caveolin1 −/− mice, dynein mutant mice were not lean but showed
strikingly enhanced adipose fat padswith strongly increasedWATweight
long before obesity was observed and WAT explants of dynein mutant
mice did not show changes in basal lipolysis. This suggests that lipid
droplet formation and protection of lipids from lipases were not changed
by the dynein mutation, consistent with the fact that dynein mutation
does not signiﬁcantly impair housekeeping functions of dynein but rather
decreases dynein transport upon cellular stress [4]. Despite normal basal
lipolysis, Cra/+ WAT showed decreased ability to provide an adequateFig. 9. Decreased huntingtin protein levels in dynein mutant WAT. (A) mRNA levels of
huntingtin (HTT) in theWAT fromwild-type (+/+, black columns) and dynein mutant
(Cra/+, empty columns) at 4 months of age. No signiﬁcant difference is observed.
(B) Representative Western blotting of huntingtin (HTT) and actin in the epididimary
WAT from 4-month-old +/+ and Cra/+ mice.lipolytic response to norepinephrine. Importantly, BAT norepinephrine
response was also defective and underlay the defect in thermogenesis
observed in mutant animals. Thus, a ﬁrst important result of this study is
that, besides its known role in lipid droplet formation, dynein is involved
in adipose tissue response to norepinephrine.
4.3. Mechanisms underlying dynein involvement in stimulated lipolysis
We next deﬁned the mechanisms underlying dynein function in
stimulated lipolysis. First, dynein mutation blunted the effects of
norepinephrine on HSL phosphorylation. This signaling defect was not
due to strongly impaired PKA activation but rather to a selective
inhibition of PKA-mediated HSL phosphorylation. Two lines of evidence
suggested that dynein did not impair the classical cAMP/PKA axis after
norepinephrine stimulation: ﬁrst, PKA activity appeared only mildly
decreased in Cra/+ WAT after stimulation. Second, direct activation of
adenylate cyclase by forskolin did not correct the lipolysis defect,
suggesting that the defect was either downstream adenylate cyclase or
affecting other pathways elicited by the beta-adrenergic receptors. A
number of accessory pathways have been described after beta-
adrenergic stimulation. Among them, we chose to focus on NADPH
oxidase oxidative stress production. Indeed, NADPH-oxidase-depen-
dent oxidative stress has been shown to participate in several aspects of
the transduction pathway of beta-adrenergic receptors, independently
of PKA [22,39] although whether norepinephrine actually increases
[22,24] or decreases [21] oxidative stress production in adipocytes
remains controversial. Furthermore, NADPH activation has been shown
to be downstream the cellular effects of microtubules depolymerising
drugs [25,26]. Here, we observed that norepinephrine decreased H2O2
production in wild-type adipocytes, a result similar to that of Krieger
and collaborators [21]. Contrasting with this, H2O2 production was
68 J. Eschbach et al. / Biochimica et Biophysica Acta 1812 (2011) 59–69potently increased in Cra/+ adipocytes suggesting that an inhibitory
mechanism was lost in dynein mutant WAT. Consistent with increased
oxidative stress, superoxide production in response to norepinephrine
was noticeable in dynein mutant adipocytes and we observed an
oxidative stress-like transcriptional ﬁngerprint in WAT. Interestingly,
previous work has indicated that NADPH oxidase inhibition after beta-
adrenergic stimulation was due to the beta-gamma subunits of G(s)
protein [21] and that thedynein light chain Tctex1 is knowntomodulate
G protein beta gamma subunits [40]. Another dynein light chain, LC8,
was involved in the attenuation of NFkappaB signaling after NADPH
oxidase stimulation by oxidative stress [41]. Whether dynein mutation
leads to abnormal function of Tctex1 and/or LC8 underlying increased
NADPH-oxidase-dependent oxidative stress in Cra/+WAT will require
further work. Our study, however, shows that NADPH-oxidase ROS
production was responsible for at least part of the inhibition of lipolysis
since HSL phosphorylation was restored by apocynin, a speciﬁc NAPDH
oxidase inhibitor [42] and since apocynin treatment also reverted the
defect in lipolysis.4.4. Potential consequences for Huntington's disease
Dynein is especially known for its involvement in neurodegener-
ative diseases, especially in motor neuron diseases and in Hunting-
ton's disease (HD). More speciﬁcally for HD, mutant Huntingtin
decreases dynein activity, and this might be crucial for the
pathogenesis [9,10]. Interestingly, our current results show that
huntingtin protein levels are decreased in dynein mutant mice. The
mechanisms underlying this defect, as well as its relationshipwith the
phenotype described here, are still elusive. It is striking to note that a
very similar metabolic phenotype was observed in HD animal models
(for review, see Refs. [43–45]). Notably, R6/2 transgenic mice show
increased adiposity [14,28], in the absence of obesity [14,28,29].
Adipose tissue of R6/2 mice show decreased isoproterenol-stimulated
lipolysis [14] and brown adipose tissue-mediated thermogenesis was
profoundly impaired [13]. In all, the peripheral phenotype observed in
R6/2 mice was strikingly similar to dynein mutant phenotype,
suggesting that common pathways, for instance, throughmodiﬁcation
of PGC1alpha function [13,28], might be at work upon dynein
mutation and mutant huntingtin expression. To our knowledge,
similar studies in HD adipose tissues are lacking, although a large
consensus exists that HD leads to a widespread pathology besides CNS
pathology [46].5. Conclusions
In all, our study provides the ﬁrst in vivo evidence of a key role for a
molecular motor in adipose tissue physiology through its regulatory
role on reactive oxygen species production after norepinephrine
stimulation. Exploration of the contribution of dynein and its
interacting proteins to human diabetes and metabolic syndrome is
warranted. Our study also provides further support for decreased
dynein function as a potential mechanism of HD.
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